Search clinical trials for: insulin degludec/insulin aspart

Total 2805 results

Novo Nordisk A/S

Completed

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (DUAL™ I)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Russian Federation, Slovakia, Spain, Canada, Taiwan, Finland, Hungary, Malaysia, South Africa, United Kingdom, Germany, Australia, Thailand, Ireland, Puerto Rico, Singapore
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Region Örebro County
Uppsala-Örebro Regional Research Council

Completed

Treatment of Impaired Glucose Tolerance in Pregnancy (TIP)

Impaired Glucose Tolerance | Fetal Macrosomia

Sweden
Ain Shams University

Unknown

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Type 1 Diabetes Mellitus With Hypoglycemia | type1diabetes

Egypt
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Finland, Germany
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) (DUAL™ I China)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Healthy | Diabetes

Germany
Mannkind Corporation

Completed

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Diabetes Type 2

Brazil, Spain, United States, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparison of Two Insulin Aspart Formulations in Healthy Volunteers

Healthy | Diabetes

South Africa
Sanofi

Completed

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Terminated

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs (DUAL™ II Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Lise Tarnow
Novo Nordisk A/S

Completed

Insulin Analogues and Severe Hypoglycaemia

Type 1 Diabetes

Denmark
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
University of Miami

Terminated

Simplified Insulin Regimen for the Elderly

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, South Africa, Romania, Brazil, China, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
University of Cambridge
Medical University of Graz; University Hospital Inselspital, Berne; Manchester...

Completed

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_P3)

Type 1 Diabetes

United Kingdom, Austria, Switzerland
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)

Diabetes | Type 1 Diabetes

United States, Taiwan, Poland, Argentina, Japan, Slovakia, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Healthy | Diabetes

Hungary
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. (DUAL™ I Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

Diabetes | Type 2 Diabetes

United States, China, Germany, Mexico, Brazil, Canada, Japan, Korea, Republic of, Puerto Rico, Czechia, Greece
Beijing Hospital

Unknown

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes

Type 2 Diabetic Patients

China
University of Palermo

Completed

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Denmark, Hungary, Slovenia, Switzerland, Bulgaria
Novo Nordisk A/S

Completed

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Terminated

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
University of Alabama at Birmingham

Recruiting

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

Diabetes Mellitus, Type 2 | Preterm Birth | Pregnancy, High Risk | Diabetes, Gestational

United States
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Type 2 Diabetes

United States, Spain, Taiwan, Japan, Poland, Argentina, Hungary, Puerto Rico, Korea, Republic of, Slovakia
King Faisal Specialist Hospital & Research Center

Recruiting

Degludec Insulin Use in Critically Ill Patients

Hyperglycemia | Diabetes Mellitus | Critical Illness

Saudi Arabia
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China (CN-TREAT)

Diabetes Mellitus, Type 2

China
prof dr Pieter Gillard
University Hospital, Antwerp

Completed

Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec (GLADE)

Type 1 Diabetes

Belgium
Novo Nordisk A/S

Completed

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus (ReFLeCT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Switzerland, Denmark, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Enrolling by invitation

A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level (DEAL-2)

Diabetes Mellitus, Type 2

Saudi Arabia
University of Padova
Azienda Ospedaliera di Padova

Completed

Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes (Basal21)

Type 1 Diabetes Mellitus

Italy
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (CAN-TREAT)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Canada

3

Subscribe